Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 21, 2026
Expenses
$265,800
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
District of Columbia
Government bodies contacted
4
Lobbying activity
1
Legislation to stop restrictions to practices mailing oral drugs (HR 2484) Technical fix to the Inflation Reduction Act regarding drug negotiation (HR 4299) Increase in Medicare payments to physicians and an inflation update Legislative fixes to the 340B Drug Purchasing Program Site neutral payments to hospitals Misc legislation to stop pharmacy benefit manager patient abuses and low-ball reimbursement Prior authorization and step therapy issues Medicare physician fee schedule payment cuts to radiation therapy